Physician profile
Semhar Teklezgi
NPI 1578982955
$565.44
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $51.89 · 2021: $69.09 · 2023: $53.09 · 2024: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $172.74 | 2019-2024 | Xarelto |
| Philips North America LLC | $100.35 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $72.95 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.71 | 2023-2024 | Lifevest |
| Melinta Therapeutics, LLC | $27.55 | 2019 | |
| Fisher & Paykel Healthcare INC | $26.41 | 2024 | Fisher & Paykel Healthcare |
| Pfizer INC. | $26.22 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $18.00 | 2023 | Nuzyra |
| Amarin Pharma, INC. | $17.22 | 2019 | |
| Abbvie INC. | $16.43 | 2023 | Avycaz |
| Gilead Sciences, INC. | $16.14 | 2024 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $14.87 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $13.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Semhar Teklezgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.